ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund comes on the heels of a nearly $2 billion fund announced in January 2021 and launches amidst a biotech bear market.

SKYCovione, developed by the University of Washington. (UW Photo) Two COVID-19 vaccines with roots in Seattle cleared major regulatory milestones Wednesday. South Korea approved a shot developed by University of Washington researchers and Indian regulatory authorities issued an emergency use

Experimentally-determined structure of a bacterial protein, compared with structures produced by AlphaFold2 and OpenFold. (OpenFold Image) Three Seattle biotech companies are joining forces to support open-access development of protein folding and design software. The project, called OpenFold, brings together Cyrus

STAR executive director Sonya Cunningham (left) and faculty director Eve Riskin. (UW Photo) A University of Washington program to support STEM students from low-income and underserved backgrounds is now nine years old. And it aims to spread the model to